NSE · AUROPHARMA
Aurobindo Pharma Limited
Historical price visualisation is temporarily undergoing corporate data-licensing maintenance. Full interactive price and chart data will return following our upcoming authorized NSE/BSE data-feed deployment. Derived metrics (valuation ratios, market-cap rank), company financials, shareholding, corporate actions, and mutual-fund holdings remain available.
Market cap rank
#118
of 5,072 stocks
▼ 41W
Peak #114 · 21 Sep 2026
A largecap name in Healthcare, Aurobindo Pharma Limited is well-owned by domestic institutions (25% DII), is growing revenue modestly, and commands a premium earnings multiple.
Market Cap
98,508.48 Cr
P/E Ratio
28.37
P/B Ratio
2.62
ROE
9.25%
ROCE
13.74%
Dividend Yield
—
52W High
—
52W Low
—
Quarterly financials
| Metric | Q1 2026-27 | Q4 2025-26 | Q3 2025-26 | Q2 2025-26 |
|---|---|---|---|---|
| Revenue | 9,150.35 Cr | 8,853.34 Cr | 8,645.90 Cr | 8,285.70 Cr |
| Net Profit | 1,032.03 Cr | 920.84 Cr | 909.80 Cr | 848.13 Cr |
| EPS | 17.86 | 15.86 | 15.67 | 14.61 |
| Operating Profit | 1,658.47 Cr | 1,391.25 Cr | 1,496.25 Cr | 1,369.50 Cr |
Shareholding pattern
Promoter
51.88%
Public
48.12%
PUBLIC BREAKDOWN
FII
16.38%
DII
25.10%
MF (within DII)
16.71%
Individuals
5.74%
Mutual fund holdings
₹15,309.89
Cr total
218
Schemes
38
Fund Houses
₹15,309.89 Cr
Total Exposure
Quant Mutual Fund₹4,850.30 Cr (31.7%)
SBI Mutual Fund₹3,706.69 Cr (24.2%)
HDFC Mutual Fund₹3,183.93 Cr (20.8%)
UTI Mutual Fund₹764.38 Cr (5.0%)
Nippon India Mutual Fund₹425.03 Cr (2.8%)
Others₹2,379.57 Cr (15.5%)
Recent corporate actions
| Ex-Date | Type | Details |
|---|---|---|
| 17 Apr 2026 | Buyback | Buy Back |
| 08 Aug 2025 | Dividend | Interim Dividend - Rs 4 Per Share |
| 26 Aug 2024 | Other | Annual General Meeting |
| 30 Jul 2024 | Buyback | Buy Back |
| 20 Feb 2024 | Dividend | Interim Dividend - Rs 1.50 Per Share |
Need this data in your app?
Full price history, technical indicators, and every field above via one REST API call.